Skip to main content

Advertisement

SpringerLink
Log in

A prospective evaluation of chemohormonal therapy remission maintenance in advanced breast cancer

  • US-Japan Conference on Chemoendocrine Therapy
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

From October 1973 to October 1977 the ECOG prospectively evaluated cyclophosphamide, methotrexate, and fluorouracil (CMF) versus CMF plus fluoxymesterone (CMFH) maintenance therapies in responders to 6 months of induction therapy which consisted of either CMF, CMF plus prednisone (CMFP), or adriamycin plus vincristine (AV). Following the maintenance randomization 12% of the patients converted from a PR to a CR status. The median time from randomization to treatment failure was 9.5 months for CMFH and 6.7 months for CMF (p = 0.03). This difference was observed only for partial responders (p = 0.01) and not for complete responders. Patients receiving CMFH tended to maintain higher hemoglobin, leukocyte, and platelet levels, and receive a higher dosage of each of the cytotoxic drugs. The results are taken as evidence that the addition of fluoxymesterone to a maintenance CMF regimen provides a therapeutic advantage. It is hypothesized that this effect is due at least in part to fluoxymesterone associated maintenance of improved marrow function resulting in greater myelosuppressive drug delivery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Watson GW, Turner RL: Breast cancer: A new approach to therapy. Brit Med J i: 1315–1322, 1959.

    Google Scholar 

  2. Greenspan EM, Fieber M, Lesnick G, Edelman S: Response of advanced breast carcinoma to the combination of the antimetabolite, methotrexate, and the alkylating agent, thiotepa. J Mt Sinai Hosp 30: 246–267, 1963.

    Google Scholar 

  3. Greenspan EM: Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. J Mt Sinai Hosp 33: 1–17, 1966.

    Google Scholar 

  4. Cooper RG: Combination chemotherapy in hormone resistant breast cancer (Abstract). Proc AACR 10: 15, 1969.

    Google Scholar 

  5. Tormey DC, Neifeld JP. Chemotherapeutic approaches to disseminated breast cancer.In BA Stoll (ed): Breast Cancer Management — Early and Late. Heineman Medical and Year Book Pubs, London, 1977, pp 117–131.

    Google Scholar 

  6. Tormey DC, Falkson G, Simon RM, Blom J, Bull JM, Lippman ME, Li S-H, Cassidy JG, Falkson HC: A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. Cancer Clin Trials 2: 247–256, 1979.

    Google Scholar 

  7. Band PR, Tormey DC, Temkin N: Induction chemotherapy and maintenance chemohormonotherapy in metastatic breast cancer (Abstract). Proc AACR 17: 37, 1976.

    Google Scholar 

  8. Kennedy BJ, Nathanson IT: Effects of intensive sex steroid hormone therapy in advanced breat cancer. J Am Med Assoc 152: 1135–1141, 1953.

    PubMed  Google Scholar 

  9. Gardner FH, Pringle JC Jr: Androgens and erythropoiesis. II. Treatment of myeloid metaplasia. N Engl J Med 264: 103–111, 1961.

    PubMed  Google Scholar 

  10. Kennedy BJ: Stimulation of erythropoiesis by androgenic hormones. Ann Intern Med 57: 917–936, 1962.

    PubMed  Google Scholar 

  11. Brodsky I: The role of androgens and anabolic steroids in the treatment of cancer. Sem Drug Treatment 3: 15–25, 1973.

    Google Scholar 

  12. Singer JW, Adamson JW: Steroids and hematopoiesis. III. The response of granulocytic and erythroid colony-forming cells to steroids of different classes. Blood 48: 855–864, 1976.

    PubMed  Google Scholar 

  13. Biedermann C, Obolensky W, Scoglio P, Zurcher WO: Traitement anabolisant associé à un antimitotique dans le but de prévenir la chute des leucocytes sanguins. Revue Thérapeutique 23: 509–515, 1966.

    Google Scholar 

  14. Rosenblum AL, Carbone PP: Androgenic hormones and human granulopoiesisin vitro. Blood 43: 351–356, 1974.

    PubMed  Google Scholar 

  15. Huys J, van Vaerenbergh PM: The effect of nandrolone decanoate on bone marrow suppression induced by cytostatic agents. Clin Oncol 2: 207–214, 1976.

    PubMed  Google Scholar 

  16. Donati RM, Gallagher NI: Reversion by testosterone (NSC-9700) of radiation induced hematologic depression in rats. Cancer Chemother Rep. 50: 649–653, 1966.

    PubMed  Google Scholar 

  17. Hoogstraten B, Irwin L, Ahmann D, Band P, Fink DI, Greenspan E, Sears ME, Sedransk N, Smalley R., Talley R, Tormey DC, Carter S: Breast cancer: proposed guidelinesreport from the combination chemotherapy trials working group,In PP carbone and ME Sears (eds): Breast Cancer: Suggested Protocol Guidelines for Combination Chemo-therapy Trials and for Combined Modality Trials, DHEW Publication No. (NIH) 77–1192, 1977, pp 4–19.

  18. Tormey DC, Gelman R, Band P, Falkson G: Impact of chemohormonal therapy upon maintenance in advanced breast cancer (Abstract). Proc ASCO 20: 356, 1979.

    Google Scholar 

  19. Fisher RA: Statistical Methods for Research Workers. Edinburgh, 1934.

  20. Cox DR: Regression models and life tables. J Royal Statistical Society, Series B 34: 187–202, 1972.

    Google Scholar 

  21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statistical Assoc 53: 457–481, 1958.

    Google Scholar 

  22. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J Royal Statistical Society, Series A 135: 185–198, 1972.

    Google Scholar 

  23. Wilcoxon F: Individual comparisons by ranking methods. Biometrics 1: 80–83, 1945.

    Google Scholar 

  24. Canellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC: Cyclical combination chemotherapy for advanced breast carcinoma. Brit Med J 1: 218–220, 1974.

    PubMed  Google Scholar 

  25. Smalley RV, Murphy S, Huguley CM, Jr, Bartolucci AA: Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 36: 3911–3916, 1976.

    PubMed  Google Scholar 

  26. Stolfi RL, Sawyer RC, Nayak R, Spiegelman S, Martin DS: Protection by testosterone from fluorouracil-induced toxicity without loss of anti-cancer activity against autochthonous murine breast tumors. Cancer Res 40: 2730–2735, 1980.

    PubMed  Google Scholar 

  27. Tisman G: Lithium carbonate protection against druginduced leukopenia in lymphosarcoma patients. Haema-tologica 2: 1509–1514, 1974.

    Google Scholar 

  28. Greco FA, Brereton HD, Pomeroy T: Lithium carbonate attenuation of neutropenia from cancer chemotherapy (Abstract). Proc AACR 17: 250, 1976.

    Google Scholar 

  29. Barrett AJ, Hugh-Jones K, Newton K, Watson JG: Lithium therapy in aplastic anemia. Lancet i: 202, 1977.

    Google Scholar 

  30. Catane R, Kaufman J, Mittelman A, Murphy GP: Attenuation of myelosuppression with lithium. N Engl J Med 297: 452–453, 1977.

    PubMed  Google Scholar 

  31. Stein RS, Beaman C, Ali MY, Hansen R, Jenkins DD, Jume'an HG: Lithium carbonate attenuation of chemo-therapy-induced neutropenia. N Engl J Med 297: 430–431, 1977.

    PubMed  Google Scholar 

  32. Lyman GH, Williams CC, Preston D: A prospective randomized study of the effect of lithium carbonate (L) on the granulocytopenia and incidence of infection associated with intensive chemotherapy and radiation therapy for undifferentiated small cell bronchogenic carcinoma (USCBC) (Abstract). Blood 52 (Suppl 1): 228, 1978.

    Google Scholar 

  33. Rothstein G, Clarkson DR, Larsen W, Grosser BI, Athens JW: Effect of lithium on neutrophil mass and production. N Engl J Med 298: 178–180, 1978.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wisconsin Clinical Cancer Center, CA 21115, Madison, WI, USA

    Douglass C. Tormey M.D., Ph.D.

  2. Sidney Farber Cancer Institute, CA 23318, Boston, MA, USA

    Rebecca Gelman Ph.D. & Madeline Bauer Ph.D.

  3. Institut du cancer de Montreal, Centre Hospitalier Notre-Dame, CA 21653, Montreal, Quebec, Canada

    Pierre R. Band M.D.

  4. National Cancer Institute, Washington, D.C., USA

    Mary Sears M.D.

  5. University of Rochester Cancer Center, CA 11083, Rochester, NY, USA

    James C. Arseneau M.D.

  6. University of Pretoria, CA 21692, Pretoria, South Africa

    Geoffrey Falkson M.D.

Authors
  1. Douglass C. Tormey M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rebecca Gelman Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre R. Band M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mary Sears M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Madeline Bauer Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. James C. Arseneau M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Geoffrey Falkson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for reprints: Douglass C. Tormey, M.D., Ph.D., Wisconsin Clinical Cancer Center, Room K4/632 Clinical Sciences Center, 600 Highland Avenue, Madison, WI 53792.

The results of this trial were presented in part at the American Society of Clinical Oncology Meeting in April 1979.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tormey, D.C., Gelman, R., Band, P.R. et al. A prospective evaluation of chemohormonal therapy remission maintenance in advanced breast cancer. Breast Cancer Res Tr 1, 111–119 (1981). https://doi.org/10.1007/BF01805863

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01805863

Keywords

Search

Navigation